Abstract
Sorbitol dehydrogenase (SDH) is the second enzyme in the polyol pathway of glucose metabolism and is a possible target for the treatment of the complications of diabetes. In this study the molecular modelling program DOCK was used to analyse 249,071 compounds from the National Cancer Institute Database and predict those with high affinity for SDH. From a total of 21 tested the 7 compounds including flavin adenine dinucleotide disodium hydrate, (+)- Amethopterin, 3-hydroxy-2-napthoic(2-hydroxybenzylidene) hydrazide, folic acid, N-2,4-dinitrophenyl-L-cysteic acid, Vanillin azine and 1H-indole-2,3-dione,5-bromo-6-nitro-1-(2,3,4-tri-O-acetyl-α-L-arabinopyranosyl)-(9Cl), were shown to inhibit SDH and displayed IC50 values of 0.192 μM, 1.1 μM, 1.2 μM, 4.5 μM, 5.3 μM, 7 μM and 28 μM, respectively. These compounds may aid the design of pharmaceutical agents for the treatment of diabetes complications.
Keywords: SDH inhibitor, Zn atom, NCI database, spectrophotometer, DOCK program
Medicinal Chemistry
Title: Discovery of Potential Sorbitol Dehydrogenase Inhibitors from Virtual Screening
Volume: 2 Issue: 3
Author(s): Ossama El-Kabbani, Deborah A. Carper, Takeshi Iwata and Connie Darmanin
Affiliation:
Keywords: SDH inhibitor, Zn atom, NCI database, spectrophotometer, DOCK program
Abstract: Sorbitol dehydrogenase (SDH) is the second enzyme in the polyol pathway of glucose metabolism and is a possible target for the treatment of the complications of diabetes. In this study the molecular modelling program DOCK was used to analyse 249,071 compounds from the National Cancer Institute Database and predict those with high affinity for SDH. From a total of 21 tested the 7 compounds including flavin adenine dinucleotide disodium hydrate, (+)- Amethopterin, 3-hydroxy-2-napthoic(2-hydroxybenzylidene) hydrazide, folic acid, N-2,4-dinitrophenyl-L-cysteic acid, Vanillin azine and 1H-indole-2,3-dione,5-bromo-6-nitro-1-(2,3,4-tri-O-acetyl-α-L-arabinopyranosyl)-(9Cl), were shown to inhibit SDH and displayed IC50 values of 0.192 μM, 1.1 μM, 1.2 μM, 4.5 μM, 5.3 μM, 7 μM and 28 μM, respectively. These compounds may aid the design of pharmaceutical agents for the treatment of diabetes complications.
Export Options
About this article
Cite this article as:
El-Kabbani Ossama, Carper A. Deborah, Iwata Takeshi and Darmanin Connie, Discovery of Potential Sorbitol Dehydrogenase Inhibitors from Virtual Screening, Medicinal Chemistry 2006; 2 (3) . https://dx.doi.org/10.2174/157340606776930772
DOI https://dx.doi.org/10.2174/157340606776930772 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Profiles of Two Glycaemia Modifying Drugs on the Expression of Rat and Human Sulfotransferases
Current Drug Metabolism Advances in the Chemistry of Saccharins: From Synthetic Novelties Towards Biologically Active Compounds
Current Medicinal Chemistry Potential Drugs and Methods for Preventing or Delaying the Progression of Huntington's Disease
Recent Patents on CNS Drug Discovery (Discontinued) Commentary Research Highlights (Amyloid β-Peptide and Alzheimer’s Disease: It’s All the RAGE)
CNS & Neurological Disorders - Drug Targets Depression and Quality of Life in Patients with Diabetes: A Systematic Review from the European Depression in Diabetes (EDID) Research Consortium
Current Diabetes Reviews Advanced Glycation End Products and Cardiovascular Disease
Current Diabetes Reviews The Renin Inhibitor Aliskiren as Novel Treatment for Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry Editorial [Hot Topic: Chelating Agents in Different Human Diseases (Guest Editor: Valeria Marina Nurchi)]
Current Medicinal Chemistry Melatonin as a Pleiotropic Molecule with Therapeutic Potential for Type 2 Diabetes and Cancer
Current Medicinal Chemistry Gene Therapy for Diabetes Mellitus
Current Molecular Medicine Calcium Antagonists: A Ready Prescription for Treating Infectious Diseases?
Current Topics in Medicinal Chemistry Exploring the Mechanism of Lingzhu San in Treating Febrile Seizures by Using Network Pharmacology
Combinatorial Chemistry & High Throughput Screening Role of Long Non-coding RNAs in the Pathogenesis of Alzheimer’s and Parkinson’s Diseases
Current Aging Science PPARs and Diabetes-Associated Atherosclerosis
Current Pharmaceutical Design Natural Products Modulating Autophagy Pathway Against the Pathogenesis of Diabetes Mellitus
Current Drug Targets Spinal Muscular Atrophy: Molecular Mechanisms
Current Molecular Medicine Application of NMR Spectroscopy in Medicinal Chemistry and Drug Discovery
Current Topics in Medicinal Chemistry Structurally Related Edaravone Analogues: Synthesis, Antiradical, Antioxidant, and Copper-Chelating Properties
CNS & Neurological Disorders - Drug Targets The Cannabinoids Switch of Oxidative Stress: A Double-Edged Sword
Mini-Reviews in Organic Chemistry